US Patent

US10898444 — Extended release multiparticulates of ranolazine

Formulation · Assigned to Sun Pharmaceutical Industries Ltd · Expires 2038-01-24 · 12y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an extended release multiparticulate composition of ranolazine for oral administration, which is bioequivalent to an existing extended release tablet.

USPTO Abstract

The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foods or liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulate composition and method of treatment of patients suffering from angina by administering said composition.

Drugs covered by this patent

Patent Metadata

Patent number
US10898444
Jurisdiction
US
Classification
Formulation
Expires
2038-01-24
Drug substance claim
No
Drug product claim
Yes
Assignee
Sun Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.